Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Cabozantinib Plus Pembrolizumab for Metastatic sqNSCLC
NCT05613413Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Dec 2022
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in squamous cell carcinoma of the lung (SCCL), sponsored by University of Illinois Chicago. Primary endpoint: Progression-Free Survival at 24 months. Started Dec 2022; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05613413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613413.